The p53 tumor-suppressor gene is inactivated in over 50% of all human cancers. In normal cells, p53 induces growth arrest and apoptosis in response to DNA damage. We show that p53 acts as potent tumorsuppressor gene independent of its well-documented eects on tumor-cell proliferation and apoptosis. p53 activates target genes in a murine ®brosarcoma cell-line but does not aect tumor cell-cycle progression or survival. Exogenous expression of wt-p53 does, however, block the angiogenic potential of the tumor cells resulting in formation of dormant tumors in vivo. These data provide evidence that: (1) p53 acts as a tumor suppressor gene independent of its anti-proliferative eects; (2) By inhibiting angiogenesis p53 can indirectly induce apoptosis in vivo but not in vitro; (3) p53-gene therapy which alters a tumors angiogenic potential, can revert tumors to a dormant phenotype.
Introduction
Tumorigenesis is a multistep process involving sequential genetic changes that results in uncontroled cell-proliferation (Vogelstein and Kinzler, 1993) . The ability of the tumor to manipulate its environment and trigger an angiogenic response is a critical step in tumor development. Indirect, and more recently, direct evidence show that tumors do not grow larger than a few millimeters in size unless vascularized by the host (Folkman, 1995) . Growth of capillaries into the tumor increases tumor cell survival resulting in an increase in tumor volume. The ability of the tumor to induce blood vessel formation is acquired during tumor progression. Both studies of transgenic model systems and clinical evidence suggest that this switch can occur as a distinct step before progression to a neoplastic phenotype . The switch to an angiogenic phenotype can be achieved by either epigenetic or genetic changes or both. This is exempli®ed by the accumulation of vascular endothelial growth factor (VEGF) mRNA during hypoxia, or up-regulation of VEGF by the presence of a mutated ras gene (Shweiki et al., 1992; Rak et al., 1995; Grugel et al., 1995) . The switch to an angiogenic phenotype has also been associated with the inactivation of the p53 tumor suppressor gene. The loss of the remaining wild type allele in ®broblasts from Li ± Fraumeni patients during cultivation results in down-regulation of the angiogenesis inhibitor thrombospondin 1 and concomitant with a switch to an angio-stimulatory phenotype (Dameron et al., 1994) . Furthermore, induction of expression of wt p53 in a glioblastoma cell-line stimulates the secretion of an as yet unidenti®ed angiogenesis inhibitor into the conditioned medium (Van Meir et al., 1994) .
Several independent reports which show that tumors become angiogenic either by up-regulating angiogenesis stimulators or down-regulating angiogenesis inhibitors suggest that tumor neovascularization is tightly regulated by the balance between stimulators and inhibitors (Bouck et al., 1996) . The angiogenic phenotype of tumors can be reversed by angiogenesis inihibitors. An example of this is the Lewis lung carcinoma transplantation model where the primary tumor is angiogenic but generates a circulating angiogenesis inhibitor, angiostatin, that inhibits vascularization of distant metastasis (O'Reilly et al., 1994) . Systemic treatment with angiogenesis inhibitors maintains dormancy of these metastases even after the primary tumor is removed (Holmgren et al., 1995) . This state of dormancy is characterized by a state of no growth where proliferation is balanced by cell death by apoptosis (Holmgren et al., 1995; Holmgren, 1996) . Escape from dormancy occurs when treatment with angiogenesis inhibitor is stopped and tumors induce blood vessel formation. These studies suggest that the main eect of controling angiogenesis in tumors is to elevate the incidence of cell death by apoptosis. This has now been shown for several anti-angiogenic compounds such as TNP-470, Angiostatin, Platelet factor 4 and Endostatin (O'Reilly et al., 1994 (O'Reilly et al., , 1997 Holmgren et al., 1995; Parangi et al., 1996; Tanaka et al., 1996) . p53 is inactivated in over 50% of all human tumors, including sarcomas, indicating that the loss of p53 activity is a critical step during tumorigenesis (Hollstein et al., 1991) . Furthermore, silencing of p53 by homologous recombination in mice results in an increased incidence of tumors, primarily sarcomas and lymphomas (Williams et al., 1994) . The responsiveness to cancer therapeutic agents such as radiation and chemotherapy is signi®cantly lower in p53 de®cient tumor cells . p53 is induced after DNA damage resulting in cell cycle arrest and apoptosis. Reconstitution of wt-p53 expression in a number of tumor cells has furthermore been reported to cause cell-cycle arrest or apoptosis (Diller et al., 1990; Martinez et al., 1991 , Yonisch-Rouch et al., 1991 . In this paper we have studied whether shifting the angiogenic balance by reintroducing wt-p53 could revert a fully malignant cell to dormancy. Studies of the in¯uence of p53 on angiogenesis are complicated by the direct eects of p53 on cell proliferation and survival. We have therefore studied the eect of p53 on tumorigenesis in the T241 ®brosarcoma cell-line in which reconstitution of wt-p53 expression activates target genes but does not induce cell-cycle arrest or apoptosis. This makes it possible to dissect out p53-mediated eects on angiogenesis from its direct eect on tumor cell growth and survival.
Results

Regulation of p53-responsive genes in T241 ®brosarcoma
The T241 cell line is a malignant ®brosarcoma that produces metastases in lungs when transplanted into syngeneic mice. The expression of endogenous p53 in T241 was assessed by immunostaining. Cells were immunostained with the monoclonal antibody PAb 421 which detects both wt and mutant p53. No p53 expression above background could be detected in these cells (Figure 1 ) which was con®rmed by immunoprecipitation (data not shown). To analyse the eect of reintroducing wt-p53, cells were cotransfected with a vector expressing temperature sensitive val135-p53 (ts-p53) (Yonisch-Rouch et al., 1991) and a vector conferring neomycin resistance. Positive clones were selected with G418 at 378C and analysed for p53 expression (Figure 1 ). The ts-p53 protein has a mutant conformation at 378C but has wt conformation at 328C. The biochemical activity of transfected wt-p53 was analysed by switching the temperature from 37 ± 328C. p53 transcriptionally activates expression of target genes via interaction with speci®c DNA sequences. These genes include the cyclin-cdk inhibitor p21 which blocks S phase entry, Bax which promotes apoptosis and thrombospondin 1 which is a negative regulator of angiogenesis. p21, Bax and thrombospondin 1 mRNA were all upregulated 4 h after shifting the T241 ts-p53 cells to 328C, con®rming that the transfected p53 protein indeed activates transcription of p53 target genes in T241 cells ( Figure 2 ).
Eect of wt-p53 on tumor cell proliferation
Next we assessed the direct eects of wt-p53 expression on T241 cell proliferation and apoptosis. Cell cycle progression was analysed by Bromodeoxyuridine (BrdU) labeling 24 h after incubation of cells at 328C. Analysis of the percentage of cells labeled with BrdU showed no dierence between cells transfected with either ts-p53 or the neomycin construct alone ( Table 1 ). The eect of wt-p53 on apoptosis was also studied during the same time period. Cells were analysed for DNA fragmentation with the TUNEL technique and the percentage of positive cells was scored under the microscope (Gavrieli et al., 1992) . No increased incidence of apoptosis was detected after induction of wt p53 by switching the T241 ts-p53 cells to 328C (Table 1 ). In addition, no increased sensitivity to Mitomycin C-induced DNA damage was detected (data not shown). These data show that although forced expression of wt-p53 transcriptionally activated target genes, the tumor cells did not respond by cellcycle arrest or apoptosis. The T241 ®brosarcoma produces highly vascularized tumors when transplanted into mice. We assessed whether wt-p53 expression could block this highly angiogenic phenotype in vitro. The eect of p53 on the endothelial-stimulatory activity in conditioned medium (CM) of T241 was therefore studied. Conditioned medium was collected for 40 h at 37 or 328C. The presence of endothelial stimulatory or inhibitory activity was measured in a bovine aortic endothelial cells in a 3-day proliferation assay. CM collected at 378C from ts-p53 transfected cells stimulated endothelial cell proliferation (Figure 3 ). In contrast, CM collected at 328C inhibited fetal calf serum-stimulated endothelial cell proliferation. Transfected cells with the neomycin resistance marker alone stimulated endothelial cell proliferation at both temperatures, excluding an eect of the temperature shift itself on the angiogenic phenotype.
Eect of wt-p53 on tumorigenicity
Our analysis of exogenous expression of wt-p53 in T241 cells show that the cells do not respond to wt-p53 by apoptosis or G1 arrest but lose the ability to stimulate endothelial cell proliferation. To assess the eect of wt-p53 on tumorigenicity, ts-p53 expressing or neomycin control T241 cells were injected into syngeneic mice. Tumor cells were injected subcutaneously into the ear (ts-p53 permissive temp. 28 ± 308C) or in the abdominal¯ank (temp. 36 ± 378C resulting in mutant p53 conformation) (Meyer et al., 1985) . Injection into the¯ank resulted in vascularized tumors visible within 2 weeks. The tumor take was 100% (10/ 10 animals) for both ts-p53 expressing T241 cells and control cells. Injection of control cells into the ear also resulted in formation of vascularized tumors (14/16 tumors) (Figure 4a and c) . In contrast, ts-p53 T241 cells exhibited signi®cantly lower tumor take (4/16) of which only two were vascularized 2 months after injection (Figure 4b and c). These data indicate that p53 can act as a tumor suppressor independent of its direct eects on cell proliferation and survival. Figure 3 Eect of ts-p53 on the ability of T241 cells to stimulate endothelial proliferation. Conditioned media was collected for 40 h from T241 ts-p53 cells grown at either 378 or 328C. The endothelial stimulatory activity in the conditioned media was tested on bovine aortic endothelial cells stimulated with 2% fetal calf serum in a 3 day proliferation assay. Conditioned media was diluted 1 : 2 (blank bars) or 1 : 3 (striped bars) with fresh medium. Cell number was quanti®ed in quadruplicates by spectrophotometric readings (492/690 nm) the XTT assay. Inhibition or stimulation is expressed as percentage of control To further investigate the role of angiogenesis in the tumor suppressive activity of p53, T241 cells were infected with either wt-p53 (Ad5CMV-p53)-or LacZ (Ad5CMV-LacZ)-expressing adenovirus (Zhang et al., 1994) . This allowed us to study the eect of p53 on vascularization of the chicken chorioallantoic membrane (CAM) assay. The eciency of expression as analysed 24 h after infection, by either immunohistochemistry or b-Gal staining, was over 95%. The eect of p53 on tumor cell proliferation was assessed in a 4-day proliferation assay. No signi®cant dierence between the proliferation rates of Ad5CMV-p53 or Ad LacZ infected cells could be detected (Figure 5a ). Tumor cells were applied to the CAM of windowed eggs with a glass capillary and the eggs were allowed to grow for another 4 days. AdCMVLacZ-infected T241 cells induced a rapid angiogenic response visible at 2 ± 4 days after injection. The tumors grew in three dimensions and were in®ltrated with capillaries that displayed all the signs of tumor vessels such as high density, branching ( Figure 6a ). Although wt-p53 expressing tumor cells showed tumor-take in the CAM they did not elicit an angiogenic response (Table 2 ). Ad5CMV-p53 infected T241 cells formed white in situ tumors which grew along established vessels of the CAM (Figure 6b ). Histological analysis of Ad5CMV-p53 infected T241 tumors revealed that they consisted of only two cell layers and lacked in®ltration of capillaries (Figure 6d ). Tumor cellproliferation and apoptosis in vivo were analysed to investigate whether these tumors ®tted the same criteria of angiogenesis-restricted dormancy (Holmgren et al., 1995) . Tumor cell-proliferation was analysed by in situ staining of proliferating cell nuclear antigen (PCNA). No signi®cant dierence in the proliferation index between p53 infected cells and the LacZ control was detected. Apoptotic indexes were determined by TUNEL staining; tumors derived from Ad5CMV-LacZ infected cells had an apoptotic index of only 0.6+0.2% whereas those expressing wt-p53 had an apoptotic index of 6+2.2% (Figure 5b and c) . Thus, expression of wt-p53 in T241 cells can revert the fully malignant phenotype into a dormant phenotype. 
Discussion
In these set of experiments, we show that wt-p53 can act as a tumor suppressor gene in vivo, independent of its well documented direct eects on cell-cycle and apoptosis. Expression of wt-p53 in the T241 fibrosarcoma cell-line resulted in the loss of an angiogenic phenotype. This was shown by shifting ts-p53 transfected cells to the permissive temperature which resulted in up-regulation of the mRNA encoding the angiogenesis inhibitor thrombospondin 1 mRNA within 4 h. Furthermore, conditioned medium from ts-p53 transfected cells collected at 328C inhibited endothelial cell proliferation. Finally, cells expressing wt-p53 from an adenoviral expression vector failed to induce neovascularization in the CAM assay in vivo.
Loss of an angiogenic phenotype also correlated with loss of tumorigenicity in vivo, as showed by the lack of neovascularization in the CAM assay and the lack of tumor formation in ts-p53 permissive temperature of the mouse ear. Incubation of ts-p53-transfected T241 cells at the permissive temperature activated transcription of p53-responsive p21, Bax and thrombospondin 1 genes, consistent with the known activities of p53. However, expression of wt-p53 had no eect on T241-cell proliferation or apoptosis in vitro. These data indicate that the ®brosarcoma cells have acquired resistance downstream of p53 eector molecules. Regulation of angiogenesis by p53 has been demonstrated in ®broblasts and other tumor cell-lines in vitro. These studies were complicated by the anti-proliferative eects of p53. However, the lack of anti-proliferative eects of wt-p53 when expressed in T241 ®brosarcoma cells allowed us to dissociate the eects on angiogenesis from the known anti-proliferative activities. We found that overexpression of p53 resulted in the loss of tumor angiogenesis and growth in three dimensions. p53-expressing tumors grown in the chicken CAM grew along already established vessels to a thickness not deeper than two cell-layers. This is similar to our previous observations of dormant lung surface metastases that are inhibited by angiostatin.
The elevated incidence of apoptosis observed in p53-induced dormancy is consistent with the increased incidence of apoptosis observed in dormant tumors treated with the angiogenesis inhibitors TNP 470 and angiostatin. We suggest that p53 indirectly induces apoptosis in tumor cells by restricting the blood vessel supply in vivo. Analysis of the eects Rb and p53 inactivation on tumor formation in transgenic mice suggest that p53 is a gatekeeper controling deregulated cell proliferation. Deregulation of cell proliferation by inactivation of the retinoblastoma gene in transgenic model systems results in increased proliferation and apoptosis in the targeted tissue (Symonds et al., 1994; Williams et al., 1994) . Similar experiments in p53 de®cient mice result in decreased apoptosis and increased tumor growth is observed. We propose that this level of control may not only depend directly on p53 triggered apoptosis but also indirectly on the increased apoptosis when angiogenesis is suppressed by p53 (Figure 7 ). Increased production of angiogenesis inhibitors may therefore constitute one level of protection against expansion of cells with deregulated cell proliferation. p53 is a candidate for gene-therapy in a number of human cancers. A major rationale for the introduction of p53 is to increase the rate of spontaneous and chemotherapy-induced tumor apoptosis. Our results provide an additional rationale, introduction of p53 into a highly malignant cell lines resulted in tumor suppression even when proliferation or susceptibility to DNA damage is not aected. We provide evidence that gene therapy that inhibits a tumors angiogenic potential induces a state of dormancy in vivo. p53 have an indirect anti-tumor eect by inhibiting angiogenesis and thereby increasing the rate of apoptosis. Inhibition of tumor angiogenesis has previously been shown to enhance the cure rate of chemotherapy and radiation in animal models (Teicher et al., 1992 (Teicher et al., , 1995 . Induction of tumor dormancy with wt p53 gene therapy may therefore increase ecacy of chemotherapy and radiation, resulting in enhanced ecacy of therapy.
Materials and methods
Cell culture
The T241 ®brosarcoma cell-line was cultured in DMEM 10% Fetal calf serum (Hyclone) in 10% CO 2 . For transfection experiments, 0.5610 6 cells were transfected with 5 mg of plasmid DNA (pLTRcG-p53 Val135, a gift from Moshe Oren) together with 0.2 mg of a CMV-Neo carrying G418 resistance gene (In Vitrogen) and 10 ml Lipofectin (Gibco). Transfected cells were selected with G418 at 500 mg/ml which was added 48 h after transfection. Positive clones were identi®ed by immunohistochemistry using an anti-p53 mouse monoclonal antibody PAb 421 (Pharmingen). Positive staining was visualized with ā uorescence labeled rabbit anti-mouse secondary antibody and counterstained with Hoechst 332458. Cells in S phase were labeled by a 30 min pulse of BrdU and analysed as previously described. Tunel staining was performed according to the protocol of Gavrieli et al. (1991) . For the collection of conditioned media, cells were incubated for 24 h at 328C in DMEM+10%FCS after which the medium was changed and cells were incubated for another 40 h in DMEM containing 2% FCS. The conditioned media was diluted with fresh medium with lowest dilution starting at 1 : 2. Cell proliferation was measured by plating Bovine Aortic Endothelial (BAE) cells at 10 000/well in a 24 well plate. Cell number per well was analysed after 3 days with a Coulter counter or with a XTT assay according to the protocol of the manufacturer (Boehringer Mannheim). 
Recombinant adenovirus infection
The recombinant adenoviral vector AdCMV (a kind gift from Dr J Roth) contains an expression cassette containing either wt-p53 or LacZ cDNA both under the control of the CMV promotor and an SV40 polyadenylation signal (Zhang et al., 1994) . The adenovirus vector is replication de®cient due to a deletion in the E1 gene. The viruses were produced in the E1A-expressing 293 cell-line as previously described. Eciency of infection of T241 cells was analysed by either LacZ-staining or immunostaining with p53 antibody PAb 421. Infected cultures with over 95% positivity for either LacZ or p53 were used in the CAM assay.
CAM assay
Fertilized 3-day old white Leghorn eggs were windowed using a Dremel-mototool. The window was covered with adhesive tape and eggs were incubated at 378C for 6 days. Tumor cells were collected by centrifugation at 400 g for 5 min and the resulting pellet was resuspended in PBS. Approximately 1610 5 cells in a volume of 3 ± 5 ml were applied on the CAM with a Pasteur capillary. The eggs were further incubated for another 4 days and then analysed. For histology, CAM were ®xed in 4% formaldehyde for 10 min and dehydrated and embedded in paran according to standard histological procedures. Five mm sections were cut with a microtome and analysed for apoptosis with the TUNEL staining technique. Proliferation was analysed by immunostaining with antibodies against PCNA (PC-10, Signet) as previously described (Holmgren et al., 1995) .
RNA analysis
For Northern blot analysis, cytoplasmic RNA was prepared according to Sambrook et al. (1989) . RNA was denatured and electrophoresed through a 0.9% agaroseformaldehyde gel. RNA was transferred to Hybond-N membrane (Amersham) and UV crosslinked. Filters were hybridized at 428C for 16 h in 50% formamide, 36SSC, 56Denhardts and 200 mg/ml Salmon sperm DNA and washed as previously described. The following probes were used: p21 (a gift from B Vogelstein), Bax (a gift from S. Korsmeyer), Thrombospondin 1 (a gift from P Bornstein).
Animal studies
Male 6 ± 8 week old C57Bl6 mice (Bomhult) were used. Mice were caged in groups of ®ve or less. A suspension of tumor cells in PBS of a approximately 1610 5 T241 cells were injected either subcutanously in the ear or in thē ank. Animals were anesthetized with methoxy¯uorane prior to procedures and were observed until fully recovered. At the end of experiment animals were sacri®ced with a lethal dose of CO 2 . Tumor volume was determined with calipers (width 2 6length60.52).
